Davit Batlawala, MD
Internal Medicine · Fresno, CANPI 1689038291
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 64.6% of it on its own, with 6 other manufacturers making up the rest. 2022 is the largest year on record at $268, 9.4 times the $28 reported in 2019.
Across 29 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$341
- Pfizer$81
- E.r. Squibb & Sons, L.L.C.$43
- Gilead$20
- Chiesi USA, Inc.$15
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$15
- plus $13 from 1 others
What the payments were for
- Food & beverage$528100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 17 | $341 |
| Pfizer | 5 | $81 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Gilead | 1 | $20 |
| Chiesi USA, Inc. | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Amgen | 1 | $13 |
How this compares
$528 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 16 | $182 |
| Metoprolol Tartrate | 13 | $164 |
| Pantoprazole Sodium | 28 | $125 |
| Atorvastatin Calcium | 14 | $91 |
| Amlodipine Besylate | 27 | $84 |
| Tamsulosin Hcl | 12 | $59 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $40 |
| Levofloxacin | 17 | $24 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Fresno
- John NelsonFresno$413K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.